AUPH
HealthcareAurinia Pharmaceuticals Inc.
$13.94-0.43 (-2.99%)
Prev Close
$14.37
Open
$14.43
High
$14.51
Low
$13.87
Volume
735.7K
Market Cap
$1.90B
P/E
6.70
Div Yield
—
Over the past 12 months, insider activity at Aurinia Pharmaceuticals Inc. (AUPH) has been mixed between buying and selling, with 1 insider purchase totaling $13.59M and 12 insider sales totaling $7.17M. The most recent insider transaction was by Donley Matthew Maxwell (Chief Operating Officer), who sold $473.8K worth of shares on Feb 20, 2026. Aurinia Pharmaceuticals Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.90B.
Buys (12M)
1
$13.59M
Sells (12M)
12
$7.17M
Net Activity
Net Buyer
$6.42M
Active Insiders
8
last 12 mo
AUPH Price Chart
AUPH Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 32,901 | $14.40 | $473.8K | 0 |
| Feb 20, 2026↗ | Greenleaf Peter | Chief Executive Officer | Sell | 100,171 | $14.40 | $1.44M | 0 |
| Feb 20, 2026↗ | Miller Joseph M | Chief Financial Officer | Sell | 32,424 | $14.40 | $466.9K | 0 |
| Feb 20, 2026↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 34,638 | $14.40 | $498.8K | 0 |
| Feb 2, 2026↗ | Keenan Greg | SVP, Chief Medical Officer | Sell | 11,552 | $14.53 | $167.9K | 0 |
| Jan 2, 2026↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 42,787 | $15.95 | $682.5K | 0 |
| Jan 2, 2026↗ | Greenleaf Peter | Chief Executive Officer | Sell | 113,169 | $15.95 | $1.81M | 0 |
| Jan 2, 2026↗ | Miller Joseph M | Chief Financial Officer | Sell | 40,161 | $15.95 | $640.6K | 0 |
| Jan 2, 2026↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 40,385 | $15.95 | $644.1K | 0 |
| Nov 21, 2025↗ | Bailey Jeffrey Allen | Director | Sell | 2,716 | $15.68 | $42.6K | 0 |
| Nov 21, 2025↗ | Johnson Craig A | Director | Sell | 6,039 | $15.68 | $94.7K | 0 |
| Aug 1, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 20,000 | $10.50 | $210.0K | 0 |
| Aug 1, 2025↗ | TANG KEVIN | Director | Buy | 1,300,000 | $10.45 | $13.59M | 0 |
| Mar 7, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 8,305 | $8.23 | $68.4K | 0 |
| Feb 28, 2025↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 124,893 | $7.96 | $994.4K | 0 |
| Feb 28, 2025↗ | Greenleaf Peter | Chief Executive Officer | Sell | 360,540 | $7.96 | $2.87M | 0 |
| Feb 28, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 12,239 | $8.00 | $97.9K | 0 |
| Feb 28, 2025↗ | Miller Joseph M | Chief Financial Officer | Sell | 118,013 | $7.96 | $939.6K | 0 |
| Feb 28, 2025↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 122,479 | $7.96 | $975.2K | 0 |
| Feb 28, 2025↗ | TANG KEVIN | Director | Buy | 1,600,000 | $7.95 | $12.71M | 0 |
| Dec 5, 2024↗ | TANG KEVIN | Director | Buy | 1,200,000 | $9.02 | $10.82M | 0 |
| Nov 8, 2024↗ | Bailey Jeffrey Allen | Director | Sell | 4,557 | $8.43 | $38.4K | 0 |
| Nov 8, 2024↗ | Smith Karen L. | Director | Sell | 5,241 | $8.43 | $44.2K | 0 |
| Aug 6, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 18,249 | $5.31 | $96.9K | 0 |
| May 21, 2024↗ | Balakrishnan Brinda | Director | Sell | 520 | $5.74 | $3.0K | 0 |
| May 21, 2024↗ | Billen Daniel | Director | Sell | 5,252 | $5.74 | $30.1K | 0 |
| May 21, 2024↗ | Jayne David R.W. | Director | Sell | 4,946 | $5.74 | $28.4K | 0 |
| May 21, 2024↗ | Leversage Jill | Director | Sell | 5,610 | $5.74 | $32.2K | 0 |
| May 21, 2024↗ | MacKay-Dunn R. Hector | Director | Sell | 5,630 | $5.74 | $32.3K | 0 |
| Mar 6, 2024↗ | Donley Matthew Maxwell | EVP, Ops & Strategy | Sell | 40,665 | $5.51 | $224.1K | 0 |
| Mar 6, 2024↗ | Greenleaf Peter | Chief Executive Officer | Sell | 126,981 | $5.60 | $711.1K | 0 |
| Mar 6, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 17,777 | $5.60 | $99.6K | 0 |
| Mar 6, 2024↗ | Miller Joseph M | Chief Financial Officer | Sell | 34,811 | $5.60 | $194.9K | 0 |
| Mar 6, 2024↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 57,745 | $5.60 | $323.4K | 0 |
| Feb 27, 2024↗ | Knappertz Volker | EVP, Research and Development | Sell | 4,930 | $6.10 | $30.1K | 0 |
| Feb 20, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 15,867 | $5.48 | $87.0K | 0 |
| Feb 20, 2024↗ | Knappertz Volker | EVP, Research and Development | Sell | 25,146 | $5.48 | $137.8K | 0 |
| May 18, 2023↗ | Billen Daniel | Director | Sell | 4,650 | $11.26 | $52.4K | 0 |
| May 18, 2023↗ | Hagan Joseph P | Director | Sell | 272 | $10.58 | $2.9K | 0 |
| May 18, 2023↗ | Jayne David R.W. | Director | Sell | 8,733 | $11.26 | $98.3K | 0 |
| May 18, 2023↗ | Leversage Jill | Director | Sell | 4,815 | $11.26 | $54.2K | 0 |
| May 18, 2023↗ | MacKay-Dunn R. Hector | Director | Sell | 4,818 | $11.26 | $54.3K | 0 |
| Mar 2, 2023↗ | Greenleaf Peter | Chief Executive Officer | Sell | 32,750 | $8.94 | $292.8K | 0 |
| Mar 2, 2023↗ | Miller Joseph M | Chief Financial Officer | Sell | 11,296 | $8.94 | $101.0K | 0 |
| Mar 2, 2023↗ | MILNE GEORGE M JR | Director | Buy | 20,000 | $8.91 | $178.3K | 0 |
| Mar 2, 2023↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 19,402 | $8.94 | $173.5K | 0 |
| Nov 21, 2022↗ | Donley Matthew Maxwell | Ex VP, Internal Operations | Buy | 10,000 | $4.66 | $46.6K | 0 |
| Nov 9, 2022↗ | Habig Scott Michael | Chief Commercial Officer | Buy | 5,000 | $5.02 | $25.1K | 0 |
| Nov 7, 2022↗ | Martin Michael Robert | Chief Business Officer | Buy | 30,000 | $5.16 | $154.8K | 0 |
| Mar 9, 2022↗ | MacKay-Dunn R. Hector | Director | Buy | 5,000 | $11.00 | $55.0K | 0 |
| Mar 4, 2022↗ | MILNE GEORGE M JR | Director | Buy | 5,000 | $10.82 | $54.1K | 0 |
| Mar 2, 2022↗ | Colao Massimilano | Chief Commercial Officer | Sell | 3,205 | $12.01 | $38.5K | 0 |
| Mar 2, 2022↗ | Donley Matthew Maxwell | Ex VP, Intern'l Operations | Sell | 3,052 | $12.01 | $36.7K | 0 |
| Mar 2, 2022↗ | Greenleaf Peter | Chief Executive Officer | Sell | 9,068 | $12.01 | $108.9K | 0 |
| Mar 2, 2022↗ | Huizinga Robert Bindert | EVP of Research | Sell | 4,849 | $12.01 | $58.2K | 0 |
| Mar 2, 2022↗ | Martin Michael Robert | Chief Business Officer | Sell | 4,849 | $12.01 | $58.2K | 0 |
| Mar 2, 2022↗ | Miller Joseph M | Chief Financial Officer | Sell | 3,060 | $12.01 | $36.8K | 0 |
| Mar 2, 2022↗ | Solomons Neil | Chief Medical Officer | Sell | 4,846 | $12.01 | $58.2K | 0 |
| Jan 3, 2022↗ | Hagan Joseph P | Director | Sell | 40,000 | $22.59 | $903.6K | 0 |
| Dec 13, 2021↗ | Leversage Jill | Director | Buy | 1,600 | $20.04 | $32.1K | 0 |
| Nov 9, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 150,000 | $30.25 | $4.54M | 0 |
| Nov 9, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 250,000 | $30.03 | $7.51M | 0 |
| Nov 1, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 45,000 | $31.64 | $1.42M | 0 |
| Nov 1, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 45,000 | $31.64 | $1.42M | 0 |
| Oct 25, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 130,000 | $29.75 | $3.87M | 0 |
| Sep 21, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 32,500 | $23.99 | $779.5K | 0 |
| Sep 20, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 116,000 | $23.44 | $2.72M | 0 |
| Sep 14, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 44,000 | $21.78 | $958.2K | 0 |
| Sep 10, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 32,500 | $21.15 | $687.3K | 0 |
| Sep 10, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 115,000 | $20.89 | $2.40M | 0 |
| Sep 10, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 150,000 | $19.84 | $2.98M | 0 |
| Sep 7, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 5,000 | $18.30 | $91.5K | 0 |
| Sep 7, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 7,500 | $18.10 | $135.8K | 0 |
| Aug 26, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 22,500 | $17.81 | $400.7K | 0 |
| Aug 25, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 5,000 | $15.85 | $79.3K | 0 |
| Aug 9, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $16.01 | $80.0K | 0 |
| Aug 9, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 45,000 | $16.03 | $721.4K | 0 |
| Jul 28, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $13.86 | $69.3K | 0 |
| Jun 22, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $13.76 | $68.8K | 0 |
| May 11, 2021↗ | Donley Matthew Maxwell | Ex VP, Intern'l Operations | Buy | 9,900 | $10.07 | $99.7K | 0 |
| May 11, 2021↗ | Greenleaf Peter | Chief Executive Officer | Buy | 5,125 | $10.71 | $54.9K | 0 |
| May 11, 2021↗ | Leversage Jill | Director | Buy | 2,500 | $10.96 | $27.4K | 0 |
| May 11, 2021↗ | MacKay-Dunn R. Hector | Director | Buy | 4,500 | $11.23 | $50.5K | 0 |
| May 11, 2021↗ | Miller Joseph M | Chief Financial Officer | Buy | 1,000 | $9.74 | $9.7K | 0 |
| Mar 12, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 40,000 | $13.49 | $539.6K | 0 |
| Mar 5, 2021↗ | MILNE GEORGE M JR | Director | Buy | 5,000 | $13.00 | $65.0K | 0 |
AUPH Insider Buying Activity
The following table shows recent insider purchases of Aurinia Pharmaceuticals Inc. (AUPH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025↗ | TANG KEVIN | Director | Buy | 1,300,000 | $10.45 | $13.59M | 0 |
| Feb 28, 2025↗ | TANG KEVIN | Director | Buy | 1,600,000 | $7.95 | $12.71M | 0 |
| Dec 5, 2024↗ | TANG KEVIN | Director | Buy | 1,200,000 | $9.02 | $10.82M | 0 |
| Mar 2, 2023↗ | MILNE GEORGE M JR | Director | Buy | 20,000 | $8.91 | $178.3K | 0 |
| Nov 21, 2022↗ | Donley Matthew Maxwell | Ex VP, Internal Operations | Buy | 10,000 | $4.66 | $46.6K | 0 |
| Nov 9, 2022↗ | Habig Scott Michael | Chief Commercial Officer | Buy | 5,000 | $5.02 | $25.1K | 0 |
| Nov 7, 2022↗ | Martin Michael Robert | Chief Business Officer | Buy | 30,000 | $5.16 | $154.8K | 0 |
| Mar 9, 2022↗ | MacKay-Dunn R. Hector | Director | Buy | 5,000 | $11.00 | $55.0K | 0 |
| Mar 4, 2022↗ | MILNE GEORGE M JR | Director | Buy | 5,000 | $10.82 | $54.1K | 0 |
| Dec 13, 2021↗ | Leversage Jill | Director | Buy | 1,600 | $20.04 | $32.1K | 0 |
| May 11, 2021↗ | Donley Matthew Maxwell | Ex VP, Intern'l Operations | Buy | 9,900 | $10.07 | $99.7K | 0 |
| May 11, 2021↗ | Greenleaf Peter | Chief Executive Officer | Buy | 5,125 | $10.71 | $54.9K | 0 |
| May 11, 2021↗ | Leversage Jill | Director | Buy | 2,500 | $10.96 | $27.4K | 0 |
| May 11, 2021↗ | MacKay-Dunn R. Hector | Director | Buy | 4,500 | $11.23 | $50.5K | 0 |
| May 11, 2021↗ | Miller Joseph M | Chief Financial Officer | Buy | 1,000 | $9.74 | $9.7K | 0 |
| Mar 5, 2021↗ | MILNE GEORGE M JR | Director | Buy | 5,000 | $13.00 | $65.0K | 0 |
AUPH Insider Selling Activity
The following table shows recent insider sales of Aurinia Pharmaceuticals Inc. (AUPH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 32,901 | $14.40 | $473.8K | 0 |
| Feb 20, 2026↗ | Greenleaf Peter | Chief Executive Officer | Sell | 100,171 | $14.40 | $1.44M | 0 |
| Feb 20, 2026↗ | Miller Joseph M | Chief Financial Officer | Sell | 32,424 | $14.40 | $466.9K | 0 |
| Feb 20, 2026↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 34,638 | $14.40 | $498.8K | 0 |
| Feb 2, 2026↗ | Keenan Greg | SVP, Chief Medical Officer | Sell | 11,552 | $14.53 | $167.9K | 0 |
| Jan 2, 2026↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 42,787 | $15.95 | $682.5K | 0 |
| Jan 2, 2026↗ | Greenleaf Peter | Chief Executive Officer | Sell | 113,169 | $15.95 | $1.81M | 0 |
| Jan 2, 2026↗ | Miller Joseph M | Chief Financial Officer | Sell | 40,161 | $15.95 | $640.6K | 0 |
| Jan 2, 2026↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 40,385 | $15.95 | $644.1K | 0 |
| Nov 21, 2025↗ | Bailey Jeffrey Allen | Director | Sell | 2,716 | $15.68 | $42.6K | 0 |
| Nov 21, 2025↗ | Johnson Craig A | Director | Sell | 6,039 | $15.68 | $94.7K | 0 |
| Aug 1, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 20,000 | $10.50 | $210.0K | 0 |
| Mar 7, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 8,305 | $8.23 | $68.4K | 0 |
| Feb 28, 2025↗ | Donley Matthew Maxwell | Chief Operating Officer | Sell | 124,893 | $7.96 | $994.4K | 0 |
| Feb 28, 2025↗ | Greenleaf Peter | Chief Executive Officer | Sell | 360,540 | $7.96 | $2.87M | 0 |
| Feb 28, 2025↗ | Keenan Greg | Chief Medical Officer | Sell | 12,239 | $8.00 | $97.9K | 0 |
| Feb 28, 2025↗ | Miller Joseph M | Chief Financial Officer | Sell | 118,013 | $7.96 | $939.6K | 0 |
| Feb 28, 2025↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 122,479 | $7.96 | $975.2K | 0 |
| Nov 8, 2024↗ | Bailey Jeffrey Allen | Director | Sell | 4,557 | $8.43 | $38.4K | 0 |
| Nov 8, 2024↗ | Smith Karen L. | Director | Sell | 5,241 | $8.43 | $44.2K | 0 |
| Aug 6, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 18,249 | $5.31 | $96.9K | 0 |
| May 21, 2024↗ | Balakrishnan Brinda | Director | Sell | 520 | $5.74 | $3.0K | 0 |
| May 21, 2024↗ | Billen Daniel | Director | Sell | 5,252 | $5.74 | $30.1K | 0 |
| May 21, 2024↗ | Jayne David R.W. | Director | Sell | 4,946 | $5.74 | $28.4K | 0 |
| May 21, 2024↗ | Leversage Jill | Director | Sell | 5,610 | $5.74 | $32.2K | 0 |
| May 21, 2024↗ | MacKay-Dunn R. Hector | Director | Sell | 5,630 | $5.74 | $32.3K | 0 |
| Mar 6, 2024↗ | Donley Matthew Maxwell | EVP, Ops & Strategy | Sell | 40,665 | $5.51 | $224.1K | 0 |
| Mar 6, 2024↗ | Greenleaf Peter | Chief Executive Officer | Sell | 126,981 | $5.60 | $711.1K | 0 |
| Mar 6, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 17,777 | $5.60 | $99.6K | 0 |
| Mar 6, 2024↗ | Miller Joseph M | Chief Financial Officer | Sell | 34,811 | $5.60 | $194.9K | 0 |
| Mar 6, 2024↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 57,745 | $5.60 | $323.4K | 0 |
| Feb 27, 2024↗ | Knappertz Volker | EVP, Research and Development | Sell | 4,930 | $6.10 | $30.1K | 0 |
| Feb 20, 2024↗ | Habig Scott Michael | Chief Commercial Officer | Sell | 15,867 | $5.48 | $87.0K | 0 |
| Feb 20, 2024↗ | Knappertz Volker | EVP, Research and Development | Sell | 25,146 | $5.48 | $137.8K | 0 |
| May 18, 2023↗ | Billen Daniel | Director | Sell | 4,650 | $11.26 | $52.4K | 0 |
| May 18, 2023↗ | Hagan Joseph P | Director | Sell | 272 | $10.58 | $2.9K | 0 |
| May 18, 2023↗ | Jayne David R.W. | Director | Sell | 8,733 | $11.26 | $98.3K | 0 |
| May 18, 2023↗ | Leversage Jill | Director | Sell | 4,815 | $11.26 | $54.2K | 0 |
| May 18, 2023↗ | MacKay-Dunn R. Hector | Director | Sell | 4,818 | $11.26 | $54.3K | 0 |
| Mar 2, 2023↗ | Greenleaf Peter | Chief Executive Officer | Sell | 32,750 | $8.94 | $292.8K | 0 |
| Mar 2, 2023↗ | Miller Joseph M | Chief Financial Officer | Sell | 11,296 | $8.94 | $101.0K | 0 |
| Mar 2, 2023↗ | Robertson Stephen P. | EVP, General Counsel | Sell | 19,402 | $8.94 | $173.5K | 0 |
| Mar 2, 2022↗ | Colao Massimilano | Chief Commercial Officer | Sell | 3,205 | $12.01 | $38.5K | 0 |
| Mar 2, 2022↗ | Donley Matthew Maxwell | Ex VP, Intern'l Operations | Sell | 3,052 | $12.01 | $36.7K | 0 |
| Mar 2, 2022↗ | Greenleaf Peter | Chief Executive Officer | Sell | 9,068 | $12.01 | $108.9K | 0 |
| Mar 2, 2022↗ | Huizinga Robert Bindert | EVP of Research | Sell | 4,849 | $12.01 | $58.2K | 0 |
| Mar 2, 2022↗ | Martin Michael Robert | Chief Business Officer | Sell | 4,849 | $12.01 | $58.2K | 0 |
| Mar 2, 2022↗ | Miller Joseph M | Chief Financial Officer | Sell | 3,060 | $12.01 | $36.8K | 0 |
| Mar 2, 2022↗ | Solomons Neil | Chief Medical Officer | Sell | 4,846 | $12.01 | $58.2K | 0 |
| Jan 3, 2022↗ | Hagan Joseph P | Director | Sell | 40,000 | $22.59 | $903.6K | 0 |
| Nov 9, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 150,000 | $30.25 | $4.54M | 0 |
| Nov 9, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 250,000 | $30.03 | $7.51M | 0 |
| Nov 1, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 45,000 | $31.64 | $1.42M | 0 |
| Nov 1, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 45,000 | $31.64 | $1.42M | 0 |
| Oct 25, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 130,000 | $29.75 | $3.87M | 0 |
| Sep 21, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 32,500 | $23.99 | $779.5K | 0 |
| Sep 20, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 116,000 | $23.44 | $2.72M | 0 |
| Sep 14, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 44,000 | $21.78 | $958.2K | 0 |
| Sep 10, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 32,500 | $21.15 | $687.3K | 0 |
| Sep 10, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 115,000 | $20.89 | $2.40M | 0 |
| Sep 10, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 150,000 | $19.84 | $2.98M | 0 |
| Sep 7, 2021↗ | Huizinga Robert Bindert | EVP of Research | Sell | 5,000 | $18.30 | $91.5K | 0 |
| Sep 7, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 7,500 | $18.10 | $135.8K | 0 |
| Aug 26, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 22,500 | $17.81 | $400.7K | 0 |
| Aug 25, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 5,000 | $15.85 | $79.3K | 0 |
| Aug 9, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $16.01 | $80.0K | 0 |
| Aug 9, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 45,000 | $16.03 | $721.4K | 0 |
| Jul 28, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $13.86 | $69.3K | 0 |
| Jun 22, 2021↗ | Martin Michael Robert | Chief Business Officer | Sell | 5,000 | $13.76 | $68.8K | 0 |
| Mar 12, 2021↗ | Solomons Neil | Chief Medical Officer | Sell | 40,000 | $13.49 | $539.6K | 0 |
AUPH Insiders
Similar Stocks to AUPH
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B